HUTCHMED (China) Limited (HCM)
USD 13.86
(0.87%)
USD 13.86
(0.87%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 18.37 Million USD | 104.23% |
| 2022 | -409.77 Million USD | -21.79% |
| 2021 | -336.45 Million USD | -78.07% |
| 2020 | -188.94 Million USD | -30.29% |
| 2019 | -145.01 Million USD | -56.54% |
| 2018 | -92.64 Million USD | -73.43% |
| 2017 | -53.41 Million USD | -14.39% |
| 2016 | -46.69 Million USD | -377.91% |
| 2015 | -9.77 Million USD | -220.63% |
| 2014 | 8.1 Million USD | -29.9% |
| 2013 | 11.55 Million USD | -4.59% |
| 2012 | 12.11 Million USD | 124.77% |
| 2011 | 5.38 Million USD | 344.06% |
| 2010 | -2.2 Million USD | 52.16% |
| 2009 | -4.61 Million USD | 67.57% |
| 2008 | -14.22 Million USD | -46.33% |
| 2007 | -9.72 Million USD | -80.62% |
| 2006 | -5.38 Million USD | 6.03% |
| 2005 | -5.72 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -13.76 Million USD | 70.5% |
| 2024 Q2 | -13.76 Million USD | 0.0% |
| 2023 Q2 | 55.82 Million USD | 0.0% |
| 2023 Q4 | -46.63 Million USD | 0.0% |
| 2023 FY | 17.32 Million USD | 104.23% |
| 2023 Q1 | 55.82 Million USD | 152.93% |
| 2023 Q3 | -46.63 Million USD | -183.54% |
| 2022 FY | -409.77 Million USD | -21.79% |
| 2022 Q4 | -105.46 Million USD | 0.0% |
| 2022 Q3 | -105.46 Million USD | 46.4% |
| 2022 Q2 | -196.75 Million USD | -100.0% |
| 2022 Q1 | -98.37 Million USD | -148.47% |
| 2021 Q4 | 202.98 Million USD | 319.94% |
| 2021 FY | -336.45 Million USD | -78.07% |
| 2021 Q3 | -92.29 Million USD | -14.6% |
| 2021 Q1 | -63.2 Million USD | -6.66% |
| 2021 Q2 | -80.53 Million USD | -27.43% |
| 2020 Q4 | -59.25 Million USD | 0.0% |
| 2020 FY | -188.94 Million USD | -30.29% |
| 2020 Q2 | -45.67 Million USD | -40.57% |
| 2020 Q1 | -32.49 Million USD | -132.27% |
| 2020 Q3 | -59.25 Million USD | -29.73% |
| 2019 Q1 | -36.05 Million USD | 10.76% |
| 2019 Q2 | -35.96 Million USD | 0.25% |
| 2019 FY | -145.01 Million USD | -56.54% |
| 2019 Q3 | -35.94 Million USD | 0.06% |
| 2019 Q4 | 100.67 Million USD | 380.11% |
| 2018 Q3 | -14.78 Million USD | 48.41% |
| 2018 Q2 | -28.66 Million USD | -14.55% |
| 2018 Q1 | -25.02 Million USD | 31.85% |
| 2018 FY | -92.64 Million USD | -73.43% |
| 2018 Q4 | -40.39 Million USD | -173.17% |
| 2017 FY | -53.41 Million USD | -14.39% |
| 2017 Q3 | -18.67 Million USD | -16.25% |
| 2017 Q4 | -36.71 Million USD | -96.58% |
| 2017 Q1 | -8.03 Million USD | 47.74% |
| 2017 Q2 | -16.06 Million USD | -100.0% |
| 2016 Q1 | -7.97 Million USD | -8679.03% |
| 2016 FY | -46.69 Million USD | -377.91% |
| 2016 Q2 | -7.97 Million USD | 0.0% |
| 2016 Q4 | -15.37 Million USD | 0.0% |
| 2016 Q3 | -15.37 Million USD | -92.64% |
| 2015 Q3 | -14.47 Million USD | -90337.5% |
| 2015 FY | -9.77 Million USD | -220.63% |
| 2015 Q4 | 93 Thousand USD | 100.64% |
| 2015 Q2 | -16 Thousand USD | 0.0% |
| 2015 Q1 | -16 Thousand USD | -100.08% |
| 2014 FY | 8.1 Million USD | -29.9% |
| 2014 Q4 | 20.2 Million USD | 200.16% |
| 2014 Q2 | -2.17 Million USD | 0.0% |
| 2014 Q1 | -2.17 Million USD | 78.73% |
| 2014 Q3 | -20.17 Million USD | -829.54% |
| 2013 Q3 | 1.94 Million USD | 178.74% |
| 2013 Q1 | -2.46 Million USD | 45.62% |
| 2013 Q2 | -2.46 Million USD | 0.0% |
| 2013 FY | 11.55 Million USD | -4.59% |
| 2013 Q4 | -10.2 Million USD | -624.63% |
| 2012 FY | 12.11 Million USD | 124.77% |
| 2012 Q3 | -4.54 Million USD | 0.0% |
| 2012 Q4 | -4.54 Million USD | 0.0% |
| 2011 FY | 5.38 Million USD | 344.06% |
| 2010 FY | -2.2 Million USD | 52.16% |
| 2009 FY | -4.61 Million USD | 67.57% |
| 2008 FY | -14.22 Million USD | -46.33% |
| 2007 FY | -9.72 Million USD | -80.62% |
| 2006 FY | -5.38 Million USD | 6.03% |
| 2005 FY | -5.72 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 88.994% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | 830.553% |
| Embecta Corp. | 221.5 Million USD | 91.704% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 79.042% |
| PainReform Ltd. | -9.58 Million USD | 291.726% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 483.989% |
| SCYNEXIS, Inc. | 72.66 Million USD | 74.714% |
| Journey Medical Corporation | -2.07 Million USD | 986.397% |
| Safety Shot Inc | -12.18 Million USD | 250.811% |
| Alpha Teknova, Inc. | -35.56 Million USD | 151.669% |
| Bright Green Corporation | -8.89 Million USD | 306.661% |
| Procaps Group, S.A. | 38.97 Million USD | 52.852% |
| Alvotech | -354.86 Million USD | 105.178% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 60.88% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 221.673% |
| Cosmos Health Inc. | -21.83 Million USD | 184.168% |
| Dynavax Technologies Corporation | -37.02 Million USD | 149.625% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 111.812% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 111.529% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 483.989% |
| Theratechnologies Inc. | -10.62 Million USD | 272.909% |
| Harrow Health, Inc. | 580 Thousand USD | -3068.103% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 490.874% |
| Biofrontera Inc. | -22.67 Million USD | 181.029% |
| DURECT Corporation | -36.88 Million USD | 149.818% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 448.738% |
| Cronos Group Inc. | -81.37 Million USD | 122.581% |
| OptiNose, Inc. | -22.74 Million USD | 180.776% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 91.21% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 146.931% |
| RedHill Biopharma Ltd. | 12.63 Million USD | -45.464% |
| Organogenesis Holdings Inc. | 12.52 Million USD | -46.707% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | 523.747% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 395.855% |
| Radius Health, Inc. | -3.92 Million USD | 568.153% |
| Universe Pharmaceuticals INC | -3.52 Million USD | 621.014% |
| ProPhase Labs, Inc. | -21.61 Million USD | 185.018% |
| Phibro Animal Health Corporation | 53.31 Million USD | 65.535% |
| Procaps Group S.A. | 52.32 Million USD | 64.882% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 315.593% |
| Viatris Inc. | 766.2 Million USD | 97.602% |
| Rockwell Medical, Inc. | -6.67 Million USD | 375.487% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 449.734% |
| SIGA Technologies, Inc. | 83.62 Million USD | 78.026% |
| Tilray Brands, Inc. | -174.74 Million USD | 110.515% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | -96.924% |
| Shineco, Inc. | -17.06 Million USD | 207.671% |
| PetIQ, Inc. | 60.01 Million USD | 69.383% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | 487.926% |
| Incannex Healthcare Limited | -30.04 Million USD | 161.166% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 92.676% |
| Alimera Sciences, Inc. | -1.47 Million USD | 1349.15% |
| Silver Spike Investment Corp. | 7.34 Million USD | -150.337% |
| Assertio Holdings, Inc. | -243.53 Million USD | 107.545% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 411.843% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 234.938% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 217.834% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 191.646% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 113.33% |
| Hempacco Co., Inc. | -8.81 Million USD | 308.516% |
| Talphera, Inc. | -16.88 Million USD | 208.799% |
| Alvotech | -354.86 Million USD | 105.178% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 65.625% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 94.961% |
| Currenc Group, Inc. | -6.64 Million USD | 376.491% |
| Kamada Ltd. | 10.06 Million USD | -82.581% |
| Indivior PLC | -4 Million USD | 559.375% |
| Evoke Pharma, Inc. | -7.43 Million USD | 347.279% |
| Flora Growth Corp. | -50.35 Million USD | 136.492% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 191.646% |
| Evolus, Inc. | -49.23 Million USD | 137.323% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 90.672% |
| Akanda Corp. | -10.05 Million USD | 282.811% |